Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer - Review of current data

Oral Oncology

Volumn 51, Issue 1, 2015, Pages 12-15

  Swanson, Mark S ^a   Sinha, Uttam K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

CTLA 4; Head and neck cancer; Immunotherapy; Ipilimumab; Nivolumab; PD 1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; PDCD1 PROTEIN, HUMAN; PROGRAMMED CELL DEATH 1 RECEPTOR;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; IMMUNE SYSTEM; REVIEW; SQUAMOUS CELL CARCINOMA; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOLOGY; IMMUNOTHERAPY; TUMOR ESCAPE;

ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; CTLA-4 ANTIGEN; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR ESCAPE;

EID: 84920511157     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.10.010     Document Type: Review

References (22)

1. Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013;34:556-63.
2. Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 2014;153:145-52.
3. Ribas A. Tumor immunotherapy directed at pd-1. N Engl J Med 2012;366:2517-9.
4. Riley JL. Pd-1 signaling in primary t cells. Immunol Rev 2009;229:114-25.
5. Francisco LM, Sage PT, Sharpe AH. The pd-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-42.
6. Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of pd-l1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol 2011;47:1148-53.
7. Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP. Cytotoxic T lymphocyte antigen-4 (ctla-4) blockade enhances anti-tumor immunity by stimulating melanoma-specific T cell motility. Cancer Immunol Res 2014.
8. Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol 2013;49:1089-96.
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
10. Robert C, Thomas L, Bondarenko I, O'Day S, Garbe, C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
11. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
12. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-pd-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
13. Malm IJ, Bruno TC, Fu J, Zeng Q, Taube JM, Westra W, et al. Expression profile and in vitro blockade of Pd-1 in hpv-negative head and neck squamous cell carcinoma. Head Neck 2014.
14. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the pd-1:Pd-l1 pathway in immune resistance of hpvassociated head and neck squamous cell carcinoma. Cancer Res 2013;73:1733-41.
15. Ukpo OC, Thorstad WL, Lewis Jr JS. B7-h1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol 2013;7:113-21.
16. Zandberg DP, Strome SE. The role of the pd-l1:Pd-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014;50:627-32.
17. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. Ctla-4 and pd-1 receptors inhibit t-cell activation by distinct mechanisms. Mol Cell Biol 2005;25:9543-53.
18. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumabrefractory or -naive melanoma. J Clin Oncol 2013;31:4311-8.
19. Tanguy Y. Seiwert. e.a. A phase ib study of mk-3475 in patients with human papillomavirus (hpv)-associated and non-hpv-associated head and neck (h/n) cancer. nct01848834. In: 2014 ASCO Annual Meeting, vol. 32; 2014.
20. Segal NEA. Preliminary data from a multi-arm expansion study of medi4736, an anti-pd-l1 antibody. nct01693562. In: ASCO Annual Meeting; 2014.
21. Squibb B-M. An open label, randomized phase 3 clinical trial of nivolumab vs therapy of investigator's choice in recurrent or metastatic platinumrefractory squamous cell carcinoma of the head and neck (scchn). nct02105636; 2014.
22. Pittsburgh UO. A phase ib trial of concurrent cetuximab (erbitux®) and intensity modulated radiotherapy (imrt) with ipilimumab(yervoy®) in locally advanced head and neck cancer. nct01860430. Institute, N.C., Ed.; 2013.